



## Mithra files for bankruptcy and continues negotiations with Gedeon Richter for the sale of Neuralis and Estetra

- On Monday morning, the *Tribunal de l'Entreprise* of Liège opened bankruptcy proceedings against Mithra Pharmaceuticals SA and appointed trustees
- Mithra CDMO and Novalon SA entities are not affected by the bankruptcy as they are subject to separate judicial reorganization proceedings

**Liège, Belgium, 10 June 2024 – 19:15 CEST** – Mithra (Euronext Brussels: MITRA), a company dedicated to women's health, today announces that the *Tribunal de l'Entreprise* of Liège pronounced the opening of the bankruptcy procedure of Mithra Pharmaceuticals SA this morning.

Mithra Pharmaceuticals SA was indeed facing major financial difficulties which prevent it from fulfilling its obligations and no longer had the working capital required to pursue its activities.

[As previously announced](#), Mithra Pharmaceuticals SA had entered into negotiations with Gedeon Richter. Mithra Pharmaceuticals announces today that it continues negotiations with Gedeon Richter relating to the sale to Gedeon Richter of all shares in Neuralis SA and Estetra SRL held by Mithra Pharmaceuticals SA and specific assets of Mithra R&D SA relating to the manufacture of estetrol. It is expected that the transaction would be signed and completed as soon as reasonably possible. The Mithra CDMO and Novalon SA entities are not affected by the bankruptcy as they are subject to separate judicial reorganization proceedings. The judicial protection measures to which they are subject should, subject to the court's approval, be extended until 30 June 2024. This extension is intended to allow the different parties interested in Mithra CDMO's assets to continue their due diligence and submit binding offers by mid-month.

The amount to be received from the sale of Neuralis SA and Estetra SRL as well as certain assets of Mithra R&D SA, after deduction of financial debts, will allow to repay some amounts to the creditors as per their legal privilege. As a result, this transaction does not create any value for the shareholders of Mithra Pharmaceuticals SA.

Mithra Pharmaceuticals SA was born of the ambition to significantly improve women's health, Mithra has distinguished itself by the unwavering determination of its employees to push the boundaries of science for the common good. Their research and the progress it heralds will outlive Mithra and will continue under a different banner from now on. We all

hope that these efforts will lead to the development of new solutions that will benefit as many people as possible.

The management and Board of Directors would like to thank Mithra's shareholders and partners who have played a decisive role in the scientific advances that Mithra has made possible.

### About Mithra

*Mithra Pharmaceuticals SA (Euronext: MITRA) is a Belgian biopharmaceutical company dedicated to transforming women's health by offering new choices through innovation, with a particular focus on contraception and menopause. Mithra's goal is to develop products offering better efficacy, safety and convenience, meeting women's needs throughout their life span. Mithra explores the potential of the unique native estrogen estetrol in a wide range of applications in women health and beyond. After having successfully launched the first estetrol-based product in 2021, the contraceptive pill ESTELLE®, Mithra is now focusing on its second product DONESTA®, the next-generation hormone therapy. Mithra also offers partners a complete spectrum of solutions from early drug development, clinical batches and commercial manufacturing of complex polymeric products (vaginal ring, implants) and complex liquid injectables and biologicals (vials, pre-filled syringes or cartridges) at its technological platform Mithra CDMO. Active in more than 100 countries around the world, is headquartered in Liège, Belgium. [www.mithra.com](http://www.mithra.com)*

*ESTELLE® and DONESTA® are registered trademarks of Mithra Pharmaceuticals or one of its affiliates.*

### Important information

*The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties, and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.*

---